Side Effects & Safety
Semaglutide Cuts Heart Attack Risk by 20%: What It Means
A landmark clinical trial published in the New England Journal of Medicine found that semaglutide significantly reduced major cardiovascular events in people with obesity who don't have diabetes. For anyone on or considering GLP-1 therapy, this changes the conversation. Here's what the science actually says — and what it means for your health beyond the scale.